A Retrospective Study on the Gam-COVID-Vac (Sputnik V) COVID-19 Vaccine Short-Term Efficacy and Side Effects in Iranian Healthcare Providers
| Author | Fahimeh Safarnezhad Tameshkel | en |
| Author | Shabnam Abedin Dargoush | en |
| Author | Manizheh Goudarzi | en |
| Author | Alireza Tabibzadeh | en |
| Author | Ali Ghiaseddin | en |
| Author | Mitra Ranjbar | en |
| Author | Yousef Alimohamadi | en |
| Author | Farhad Zamani | en |
| Author | Aysan Vaez | en |
| Author | Neda Rahimian | en |
| Author | Mahin Jamshidi Makiani | en |
| Author | Farshad Divsalar | en |
| Author | Esmaeel Gholizadeh | en |
| Author | Mohammad Hadi Karbalaie Niya | en |
| Orcid | Fahimeh Safarnezhad Tameshkel [0000-0001-8953-5447] | en |
| Orcid | Alireza Tabibzadeh [0000-0003-0070-2208] | en |
| Orcid | Mitra Ranjbar [0000-0002-3865-5120] | en |
| Orcid | Farhad Zamani [0000-0001-7409-3412] | en |
| Orcid | Aysan Vaez [0000-0002-5317-3250] | en |
| Orcid | Farshad Divsalar [0000-0003-4330-3004] | en |
| Orcid | Esmaeel Gholizadeh [0000-0002-4129-4733] | en |
| Orcid | Mohammad Hadi Karbalaie Niya [0000-0002-1364-5743] | en |
| Issued Date | 2023-06-30 | en |
| Abstract | Background: The Gam-COVID-Vac (Sputnik V) COVID-19 vaccine is one of the approved vaccines which has been used in Iran. Objectives: In the present retrospective study, we evaluated the short-term efficacy and side effects of the Sputnik V vaccine against COVID-19 in Iranian healthcare providers. Methods: Healthcare workers referred to Firoozgar Hospital affiliated with the Iran University of Medical Sciences, Tehran, Iran, between March 2021 and December 2021 were assessed. Humoral immunity was evaluated against S-RBD IgG of SARS-CoV2 after Sputnik V vaccination at three phases, including days 60 (phase I), 120 (phase II), and 210 (phase III) by an anti-S RBD IgG ELISA kit. Vaccine recipients were divided into two groups based on the history of SARS-CoV2 infection. The vaccine side effects were obtained from each participant after the first and second doses. Results: A total of 65 vaccine recipients (41.5% male (27/65)) with a mean age of 35 ± 8.5 years were enrolled, of whom 41.5% had a history of COVID-19 infection. The SARS-CoV-2 IgG levels were significantly higher in vaccine recipients compared to those without a history of COVID-19 infection a month (4 vs. 6.6), three months (4.5 vs. 7.2), and six months (3.8 vs. 5.9) after vaccination (P = 0.001). Our study had 18 patients (27.7%) with vaccination breakthroughs. Conclusions: Sputnik V seems to induce high antibody levels after the second dose; however, protective antibodies declined six months after the second dose. A booster dose is highly recommended for at-risk individuals. | en |
| DOI | https://doi.org/10.5812/archcid-133173 | en |
| Keyword | COVID-19 | en |
| Keyword | Vaccine | en |
| Keyword | Sputnik V | en |
| Keyword | Iran | en |
| Publisher | Brieflands | en |
| Title | A Retrospective Study on the Gam-COVID-Vac (Sputnik V) COVID-19 Vaccine Short-Term Efficacy and Side Effects in Iranian Healthcare Providers | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- archcid-18-3-133173.pdf
- Size:
- 192.78 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF